The following are the primary outcomes to be measured : ( 1 ) the trajectories of the left ventricular ejection fraction in the follow-up period ; ( 2 ) reduction of heart disease progression rates , with progression defined as a 10 % decrease in left ventricular ejection fraction ; and ( 3 ) rate of hospital admissions attributable to dysrhythmia , heart failure or stroke due to Chagas disease .